Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRDMT1 | O14717 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 2/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318268 | 0.92 | CHKA (0.37) | TRDMT1NNMTCHKACARM1ADORA1 | |
| SCHEMBL6230190 | 0.92 | TRDMT1 (0.34) | TRDMT1NNMTCHKACARM1ADORA1 | |
| SCHEMBL6735187 | 0.90 | TRDMT1 (0.34) | TRDMT1NNMTCHKACARM1ADORA1 | |
| SCHEMBL7914645 | 0.88 | TRDMT1 (0.37) | TRDMT1NNMTCARM1ADORA1TYMP | |
| SCHEMBL2349739 | 0.87 | TRDMT1 (0.35) | TRDMT1NNMTCHKACARM1ADORA1 | |
| SCHEMBL6895651 | 0.86 | AHCY (0.35) | TRDMT1NNMTCARM1P2RX3P2RX4 | |
| SCHEMBL5396749 | 0.86 | POLB (0.31) | — | |
| SCHEMBL6898692 | 0.85 | AHCY (0.35) | TRDMT1NNMTCARM1 | |
| SCHEMBL15301771 | 0.85 | TYMP (0.41) | TRDMT1NNMTCARM1ADORA1TYMP | |
| SCHEMBL7050370 | 0.83 | NNMT (0.34) | TRDMT1NNMTCARM1ADORA1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3296306-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2022-11-09 | — | — | EP | disclosed |
| EP-3296306-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-2816053-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-7273933-B1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-6858722-B2 | Oligomer phosphoramidite compositions and processes for synthesizing the same | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040203036-A1 | Multimer polynucleotide synthesis | CHEMOGENIX GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-0983233-B1 | REAGENT USEFUL FOR SYNTHESIZING SULFURIZED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1409505-A1 | MULTIMER POLYNUCLEOTIDE SYNTHESIS | Chemogenix GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | RAVIKUMAR VASULINGA T (US) | 2003-12-11 | — | — | US | disclosed |
| US-6642373-B2 | Phosphitylating using pyridinium salt activators; forming phosphorate or phosphorothioate intersugar linkages | ISIS PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | IONIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-6610842-B1 | Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003006476-A1 | MULTIMER POLYNUCLEOTIDE SYNTHESIS | CHEMOGENIX GMBH (DE) | 2003-01-23 | — | — | WO | disclosed |
| EP-1175432-A4 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHOSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS INC (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1175432-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000068241-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | RNGTT, POLL, TYMP | TRDMT1 164/4885NNMT 1798/4885CHKA 2245/4885 |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | PHOSPHO1, OSGEP, DTYMK | TRDMT1 132/4885NNMT 633/4885CHKA 2602/4885 |
| US-20040203036-A1 | Multimer polynucleotide synthesis | NT5C3B, PCNA, POLL | TRDMT1 303/4885NNMT 425/4885CHKA 1713/4885 |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | ITPA, NUDT1, TYMP | TRDMT1 56/4885NNMT 188/4885CHKA 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.